Pola Orbis Rebuilds in China

TYO:4927

Pola Orbis Holdings is the Shizuoka-born cosmetics group behind POLA, ORBIS and Jurlique. Its Wrinkle Shot serum was the first product in Japan approved to claim wrinkle improvement, and it made the company a favourite of Chinese shoppers. Now that demand from China has cooled, the group is rebuilding how it sells there while leaning on ORBIS and cost control at home.

Company overview

A beauty company built on people

POLA grew through a network of independent sales consultants, often called “POLA ladies”, who sold skincare door to door and later through small neighbourhood salons. The model gave POLA close, repeat relationships with customers and high price points, which is unusual for a mass-market Japanese brand.

The group later added very different businesses under one holding company:

• POLA — premium, research-led skincare sold through consultants, department stores and its own shops.
• ORBIS — oil-free, mid-priced skincare that started as a mail-order brand and now sells heavily online.
• Jurlique — an Australian botanical skincare brand acquired in 2012, the group’s main bet on Western markets.
• DECENCIA — skincare for sensitive skin, sold mainly online.

Wrinkle Shot and the China boom

A regulatory first

In January 2017, POLA launched Wrinkle Shot Medical Serum. It was the first product approved by Japan’s health ministry as a quasi-drug that can claim to improve wrinkles. The active ingredient, NEI-L1, came out of roughly 15 years of in-house research. The serum became one of the best-known Japanese skincare launches of the decade.

Riding inbound and cross-border demand

The launch arrived at the peak of Chinese tourist shopping in Japan. A large share of POLA’s premium sales came from visitors and resellers, known as daigou, who bought in Japan and resold in China. China also became POLA’s most important overseas market through department stores and e-commerce platforms.

Why China needs rebuilding

That growth engine has weakened. In FY2025 the POLA brand reported lower sales both in Japan and overseas. The company pointed to two causes:

• Slower consumer spending in China — premium cosmetics have been one of the categories hit hardest by the country’s slowdown, and local brands are taking share.
• Curbing the secondary market — POLA has deliberately limited bulk buying for resale. This protects pricing and brand image, but it removes sales that used to look like Japanese domestic demand.

The reset in China is less about opening more counters and more about selling directly to Chinese consumers at stable prices: tighter control of channels, more emphasis on official online stores, and products positioned on clinical evidence rather than on “made in Japan” alone.

ORBIS and cost control carry the group

While POLA works through its China problem, ORBIS has been the group’s growth brand. Its rebranding toward simple, effective skincare for younger customers has lifted sales, and the group has cut fixed costs across brands. That is why operating income rose about 13.6% in FY2025 even though group sales were flat.

What it means for overseas partners

• Retailers and distributors — POLA is now selective about channels. Partners that can guarantee price discipline and authenticity are more welcome than high-volume resellers.
• Ingredient and research partners — the group’s edge is dermatological research. Joint work on anti-ageing and sensitive-skin science fits its strategy.
• Investors — the story has moved from China-driven growth to margin repair and brand portfolio management. Watch ORBIS growth, POLA’s overseas sales and the future of Jurlique.

Conclusion

Pola Orbis built one of Japan’s most distinctive beauty businesses on personal selling and serious skin science. China turned that science into a boom, then into a dependence. The next few years will show whether the group can sell Wrinkle Shot and its successors to Chinese consumers on its own terms, at prices it controls.